On May 12, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, reported the grant of a major European patent that significantly strengthens its global intellectual property position and underscores the differentiation of its proprietary PH1 ADC payload platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The newly granted patent (European Patent No. 3684773B1), titled "Thailanstatin Analogs," provides broad composition-of-matter protection for Akari’s proprietary Thailanstatin-based payloads, engineered for use in highly targeted cytotoxic ADC therapies. The claims encompass novel analogs designed to integrate with advanced linker technologies and enable targeting across multiple tumor-associated antigens.
"This European patent grant further strengthens the foundation of our proprietary payload platform and reinforces our ability to build a differentiated ADC pipeline," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "Expanding broad composition-of-matter protection across Europe is a critical step in advancing our strategy to develop a new class of ADC therapeutics. We believe this milestone continues to enhance the value of our platform while supporting the advancement of multiple programs across tumor types and key global markets."
This European patent provides protection across a broad range of designated countries, including Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Latvia, Monaco, Macedonia, Malta, the Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovenia, the Slovak Republic, Spain, Sweden, Switzerland, Turkey and the United Kingdom, further expanding Akari’s global intellectual property estate.
Akari’s growing pipeline of novel ADCs, including AKTX-101 (targeting TROP2) and AKTX-102 (targeting CEACAM5), leverage its proprietary PH1 payload platform built around this novel IP. By targeting RNA splicing biology, Akari is advancing a novel therapeutic paradigm, disrupting fundamental cancer cell processes while simultaneously enhancing immune activation to potentially drive deeper and more durable responses.
This builds upon Akari’s rapidly expanding global IP portfolio, which includes issued patents across the United States, China, Japan, Australia, India, Mexico and Israel. Together, these protections establish a robust and defensible foundation around the Company’s PH1 payload chemistry and ADC architecture.
Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling studies with a targeted Phase 1 first-in-human clinical trial expected by mid-2027.
(Press release, Akari Therapeutics, MAY 12, 2026, View Source [SID1234665520])